Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 28 people in total — 13 in the esmolol group and 15 in the labetalol group — and all of them completed the study with no drop-outs. Both esmolol and labetalol are medications used during anaesthesia to help control blood pressure and heart rate. The trial was looking at how clearly surgeons could see the operating field during functional endoscopic sinus surgery (FESS, a procedure inside the nose and sinuses), as well as how much blood was lost and what happened to blood pressure and heart rate during the operation. The reported data shows that surgical visibility was scored using two different rating tools. On the Boezaart scale (where 0 means no bleeding and 5 means the worst bleeding), both groups scored an average of 3.1. On the Wormald scale (where 0 means no bleeding and 10 means the worst), the esmolol group averaged 6.1 and the labetalol group averaged 5.9. For the secondary measurements, the reported data shows that blood loss rate was 0.59 mL per minute in the esmolol group and 0.66 mL per minute in the labetalol group. Average blood pressure (measured as mean arterial pressure, a standard way of summarising blood pressure across a reading) was 79.7 mmHg for esmolol and 79.4 mmHg for labetalol. Average heart rate was 72 beats per minute for esmolol and 69 beats per minute for labetalol. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Chronic Rhinosinusitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with chronic rhinosinusitis (long-term sinus inflammation), with or without nasal polyps
- You are scheduled to have sinus surgery (a procedure to clear and open the sinus passages)
- You are considered generally healthy or have only a mild health condition, as assessed by your doctor before surgery
Who may not be able to join:
- You are pregnant
- You have asthma
- You have chronic obstructive pulmonary disease (COPD), a long-term lung condition
- You have a slow heart rate (bradycardia)
- You have heart failure
- You have severe kidney disease (end stage renal disease)
- You have had a stroke
- You have diabetes
- You are currently taking anti-inflammatory painkillers (such as ibuprofen or NSAIDs), aspirin, or a type of blood pressure medication called beta-blockers
- Your body mass index (BMI) is greater than 40 (confirm with trial site if you are unsure of your BMI)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Intra-operative Surgical Visibility - Boezaart Scale; Intra-operative Surgical Visibility - Wormald Scale
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.